{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T07:50:02Z","timestamp":1767340202952,"version":"3.41.2"},"reference-count":8,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T00:00:00Z","timestamp":1724630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Mavacamten in Phase 2 and 3 clinical trials was well tolerated, reduced left ventricular outflow tract obstruction (LVOTO), and improved exercise capacity and symptoms. However, due to its recent introduction in the market, there is limited evidence from real-world patients with severe\/multiple comorbidities and\/or who are exposed to potential treatment interactions. Hypertension is common in patients with hypertrophic cardiomyopathy (HCM), but its impact on the treatment of LVOTO is undefined.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Case summary<\/jats:title>\n                  <jats:p>A 55-year-old man with severely obstructive symptomatic HCM and Grade I arterial hypertension underwent treatment with mavacamten 5\u2005mg. He presented an accelerated hypertension from Day 10 of treatment. On admission, he reported improvement of his dyspnoea [New York Heart Association (NYHA) Class II] and NT-pro BNP decreased to 1646\u2005ng\/L. Echocardiography showed a left ventricular ejection fraction of 60% with reduced systolic anterior motion and LVOTO (max 21\u2005mmHg). Causes of secondary hypertension were excluded, and blood pressure (BP) was controlled by eplerenone and amlodipine introduction. Accelerated hypertension was concluded as a final diagnosis, and a potential causal link with the introduction of mavacamten was made. Evolution up to Day 135 proved a stabilization of the BP profile and of the LVOT gradient (max 36\u2005mmHg) as well as improvement in functional capacity (NYHA Class I).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>We hypothesize that rapid relief of excess afterload may induce alterations potentially leading to high BP in patients with impaired peripheral vascular resistances. Patients with severe obstructive HCM and hypertension should be given special attention during mavacamten titration and should self-monitor the BP during this phase.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcr\/ytae450","type":"journal-article","created":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T01:31:54Z","timestamp":1724463114000},"source":"Crossref","is-referenced-by-count":6,"title":["Accelerated hypertension following mavacamten introduction in severe obstructive hypertrophic cardiomyopathy with hypertension: a case report"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5819-204X","authenticated-orcid":false,"given":"Niccol\u00f2","family":"Maurizi","sequence":"first","affiliation":[{"name":"Service of Cardiology, Lausanne University Hospital, Rue de Bugnon 46, 1011 Lausanne , Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panagiotis","family":"Antiochos","sequence":"additional","affiliation":[{"name":"Service of Cardiology, Lausanne University Hospital, Rue de Bugnon 46, 1011 Lausanne , Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2441-5799","authenticated-orcid":false,"given":"Olivier","family":"Muller","sequence":"additional","affiliation":[{"name":"Service of Cardiology, Lausanne University Hospital, Rue de Bugnon 46, 1011 Lausanne , Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Wuerzner","sequence":"additional","affiliation":[{"name":"Service of Nephrology, Lausanne University Hospital, Rue de Bugnon 46, 1011 Lausanne , Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3083-7333","authenticated-orcid":false,"given":"Pierre","family":"Monney","sequence":"additional","affiliation":[{"name":"Service of Cardiology, Lausanne University Hospital, Rue de Bugnon 46, 1011 Lausanne , Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,8,26]]},"reference":[{"key":"2024091010420521900_ytae450-B1","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1093\/eurheartj\/ehad637","article-title":"Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy","volume":"44","author":"Braunwald","year":"2023","journal-title":"Eur Heart J"},{"key":"2024091010420521900_ytae450-B2","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, Phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"2024091010420521900_ytae450-B3","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1016\/j.jacc.2021.09.1381","article-title":"Effect of mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy","volume":"78","author":"Hegde","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2024091010420521900_ytae450-B4","doi-asserted-by":"crossref","first-page":"e010994","DOI":"10.1136\/heartasia-2017-010994","article-title":"The development or worsening of hypertension after transcatheter aortic valve replacement (TAVR) improves short-term and long-term patient outcomes","volume":"10","author":"Klinkhammer","year":"2018","journal-title":"Heart Asia"},{"key":"2024091010420521900_ytae450-B5","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jcin.2012.12.124","article-title":"Post-procedural hypertension following transcatheter aortic valve implantation: incidence and clinical significance","volume":"6","author":"Perlman","year":"2013","journal-title":"JACC Cardiovasc Interv"},{"key":"2024091010420521900_ytae450-B6","doi-asserted-by":"crossref","first-page":"E8143","DOI":"10.1073\/pnas.1809540115","article-title":"Deciphering the super relaxed state of human beta-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers","volume":"115","author":"Anderson","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024091010420521900_ytae450-B7","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jchf.2023.07.030","article-title":"Mavacamten for obstructive hypertrophic cardiomyopathy with or without hypertension: post-hoc analysis of the EXPLORER-HCM trial","volume":"12","author":"Wang","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2024091010420521900_ytae450-B8","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","article-title":"Aficamten for symptomatic obstructive hypertrophic cardiomyopathy","volume":"390","author":"Maron","year":"2024","journal-title":"N Engl J Med"}],"container-title":["European Heart Journal - Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcr\/advance-article-pdf\/doi\/10.1093\/ehjcr\/ytae450\/58918117\/ytae450.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcr\/article-pdf\/8\/9\/ytae450\/59070869\/ytae450.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcr\/article-pdf\/8\/9\/ytae450\/59070869\/ytae450.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T12:37:40Z","timestamp":1725971860000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcr\/article\/doi\/10.1093\/ehjcr\/ytae450\/7741122"}},"subtitle":[],"editor":[{"given":"Giacomo Tini","family":"Melato","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Belinda","family":"Gray","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Aiste Monika","family":"Jakstaite","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Nikesh","family":"Jathanna","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,8,26]]},"references-count":8,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcr\/ytae450","relation":{},"ISSN":["2514-2119"],"issn-type":[{"type":"electronic","value":"2514-2119"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,8,26]]},"article-number":"ytae450"}}